CR6491A - HIV IMMUNOGENIC COMPOSITIONS AND METHODS - Google Patents

HIV IMMUNOGENIC COMPOSITIONS AND METHODS

Info

Publication number
CR6491A
CR6491A CR6491A CR6491A CR6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A
Authority
CR
Costa Rica
Prior art keywords
hiv
immunogenic compositions
antigen
mammal
methods
Prior art date
Application number
CR6491A
Other languages
Spanish (es)
Inventor
B Moss Ronald
Original Assignee
Inmune Response Corp
Abr Llc
Acumer Investigacion Desarrollo S L
Antonio Jose De Jesus De San Juan Bosco Echevarria Parres
Dystar Textilfarben Gmbh Y Co Deutschland Kg
Eco Flora S A
John Larry Sanders
Ranka Seema Ajay
Sanofi Aventis
Smithjkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmune Response Corp, Abr Llc, Acumer Investigacion Desarrollo S L, Antonio Jose De Jesus De San Juan Bosco Echevarria Parres, Dystar Textilfarben Gmbh Y Co Deutschland Kg, Eco Flora S A, John Larry Sanders, Ranka Seema Ajay, Sanofi Aventis, Smithjkline Beecham Corp filed Critical Inmune Response Corp
Publication of CR6491A publication Critical patent/CR6491A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención ofrece composiciones inmugénicas que incrementan los niveles de B- quimiocina en un mamífero.Las composiciones inmugénicas contienen un antígeno de VIH, una mólecula de ácido nucleico aislada que contiene una secuencia inmunoestimuladora (ISS) y un adyuvnate. El antígeno de VIH puede ser un virus de VIH entero muerto sin la proteina de envoltura externa gp120. Alternativamente, el antígeno de VIH puede ser un virus de VIH entero muerto, o bien un antígeno p24. Se proporciona también un método para inhibir el SIDA, mediante el incremento de la producción de B-quimiciona en el mamífero mediante la administración al mamífero de una composición inmunogénica que contiene un antígeno de VIH, una molécula de ácido nucleico aislada que contiene una secuencia inmunoestimuladora (ISS) y un adyuvante.The invention offers immunogenic compositions that increase levels of B-chemokine in a mammal. Immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule that contains an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a dead whole HIV virus without the outer envelope protein gp120. Alternatively, the HIV antigen can be a dead whole HIV virus, or a p24 antigen. A method for inhibiting AIDS is also provided by increasing the production of B-chemocyte in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence. (ISS) and an adjuvant.

CR6491A 1999-05-06 2001-10-25 HIV IMMUNOGENIC COMPOSITIONS AND METHODS CR6491A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13276299P 1999-05-06 1999-05-06
US15066799P 1999-08-25 1999-08-25

Publications (1)

Publication Number Publication Date
CR6491A true CR6491A (en) 2005-05-31

Family

ID=26830710

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6491A CR6491A (en) 1999-05-06 2001-10-25 HIV IMMUNOGENIC COMPOSITIONS AND METHODS

Country Status (8)

Country Link
EP (1) EP1176978A2 (en)
AP (1) AP1891A (en)
AU (1) AU4992900A (en)
BR (1) BR0010323A (en)
CA (1) CA2372960C (en)
CR (1) CR6491A (en)
OA (1) OA11937A (en)
WO (1) WO2000067787A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (en) 1998-05-22 2007-02-28 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
ES2572834T3 (en) 1999-02-17 2016-06-02 Csl Limited Immunogenic complexes and related methods
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU5821000A (en) * 1999-06-29 2001-01-31 Smithkline Beecham Biologicals (Sa) Vaccine
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
KR100881923B1 (en) 2000-12-27 2009-02-04 다이나박스 테크놀로지 코퍼레이션 Immunostimulatory Polynucleotides and Methods of Use thereof
SG152045A1 (en) * 2001-01-26 2009-05-29 Immune Response Corp Inc Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
EP2423335B1 (en) 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
ATE411054T1 (en) 2001-08-17 2008-10-15 Coley Pharm Gmbh COMBINATION MOTIF-IMMUNO-STIMULATING OLIGONUCLEOTIDES WITH IMPROVED EFFECT
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
WO2004005476A2 (en) * 2002-07-03 2004-01-15 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CN1753687A (en) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Application of CPG oligonucleotide in the treatment of hepatitis C virus infection
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
JP5102959B2 (en) 2002-12-23 2012-12-19 ダイナバックス テクノロジーズ コーポレイション Immunostimulatory sequence oligonucleotides and methods of use thereof
MXPA06001996A (en) * 2003-08-28 2006-06-20 Immune Response Corp Inc Immunogenic hiv compositions and related methods.
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
PT2078080E (en) 2006-09-27 2015-09-18 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2010051820A1 (en) * 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
MX350258B (en) 2011-07-06 2017-08-31 Novartis Ag Cationic oil-in-water emulsions.
JP6059220B2 (en) 2011-07-06 2017-01-18 ノバルティス アーゲー Oil-in-water emulsion containing nucleic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1005368T3 (en) * 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants
EP1003850B1 (en) * 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity

Also Published As

Publication number Publication date
BR0010323A (en) 2002-01-08
AP1891A (en) 2008-09-23
WO2000067787A2 (en) 2000-11-16
AU4992900A (en) 2000-11-21
EP1176978A2 (en) 2002-02-06
CA2372960A1 (en) 2000-11-16
OA11937A (en) 2006-04-12
AP2001002300A0 (en) 2001-12-31
CA2372960C (en) 2006-03-28
WO2000067787A3 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
CR6491A (en) HIV IMMUNOGENIC COMPOSITIONS AND METHODS
NO20023829D0 (en) Proteosome influenza vaccine
CO5680456A2 (en) COMPOSITIONS OF VACCINES THAT INCLUDE LIPOOLIGOSACARIDS OF IMMUNOTIPE L2 AND / OR L3 FROM LGTB-NEISSERIA MINIGITIDIS
ES2129386T1 (en) INFLUENZA VACCINE.
ATE315404T1 (en) INFLUENZA VIRUS VACCINE COMPOSITION
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
BR0107972A (en) Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
DE69535075D1 (en) ANTIGEN-MARKED NON-INFECTIOUS RETROVIRUS-EARNED PARTICLES
ES534896A0 (en) AN IMMUNOGENIC COMPOSITION ADMINISTRABLE BY ROUTE
MX9306841A (en) UREASE BASED VACCINE AGAINST HELICOBACTER INFECTION IN MAMMALS.
AR041880A1 (en) IMMUNOGEN COMPOSITION
ATE144143T1 (en) ARTIFICIAL VACCINE AGAINST AIDS VIRUS
BR0009485A (en) Method and compositions for preventing or reducing HIV infection by using leucine aminopeptidase inhibitors
ECSP045300A (en) VIRAL ANTIGENS
FR2814958B1 (en) VACCINE COMPOSITION
ZA200107072B (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV.
CY1107446T1 (en) Anthelmintic Compositions
NO20050396L (en) Adjuvant viral particle
ES2195169T3 (en) VACCINES AGAINST CALMIDIES AND IMMUNOGENIC COMPOSITIONS CONTAINING AN EXTERNAL MEMBRANE ANTIGEN AND METHODS FOR PREPARATION.
BR0111834A (en) Adjuvant and immunogenic compositions, and method for eliciting an immune response to an antigen
DE69636285D1 (en) ISOLATED FRPB NUCLEIC ACID MOLECULE AND CORRESPONDING VACCINE
ES2421543T3 (en) Method for the preparation of PRRS viruses and proteins, and diagnostic test kits for detection
CY1112149T1 (en) REDUCTION OF INTERFERENCE BETWEEN OILS AND OILS AND ANTIGONS CONTAINING TASENERGY
WO2005021726A3 (en) Immunogenic hiv compositions and related methods
WO2005111079A3 (en) Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)